Rapid Therapeutic Science Laboratories, Inc.
Other OTCTotal Valuation
Rapid Therapeutic Science Laboratories, Inc. carries a market capitalization of 883.00, placing it among publicly traded companies globally. Its enterprise value stands at 4.30M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 883.00 |
| Enterprise Value | 4.30M |
Share Statistics
Rapid Therapeutic Science Laboratories, Inc. currently has 8.83M shares outstanding.
| Shares Outstanding | 8.83M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Rapid Therapeutic Science Laboratories, Inc. trades at a trailing price-to-earnings ratio of 8.61.
| PE Ratio | 8.61 |
| PS Ratio | N/A |
| PB Ratio | -0.05 |
| P/TBV Ratio | -0.18 |
| P/FCF Ratio | -0.58 |
| P/OCF Ratio | -0.91 |
Enterprise Valuation
| EV / Sales | N/A |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | 6.10 |
Financial Position
Rapid Therapeutic Science Laboratories, Inc. maintains a current ratio of 0.07, meaning it holds 0.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -138.21, indicating conservative leverage, while an interest coverage ratio of -0.89 demonstrates limited ability to service its debt obligations.
| Current Ratio | 0.07 |
| Quick Ratio | 0.02 |
| Debt / Equity | -138.21 |
| Debt / EBITDA | -7.23 |
| Interest Coverage | -0.89 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | 2.64 |
| Return on Invested Capital (ROIC) | -67.21 |
| Return on Capital Employed (ROCE) | -10.04 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Rapid Therapeutic Science Laboratories, Inc.'s stock has declined approximately -98.57143% over the past 52 weeks. The 50-day moving average sits at 0.00, while the 200-day moving average is 0.00.
| Beta (5Y) | N/A |
| 52-Week Price Change | -98.57143% |
| 50-Day Moving Average | 0.00 |
| 200-Day Moving Average | 0.00 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -523,619.00, while operating income came in at -547,591.00.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -547,591.00 |
| Pretax Income | 59,556.00 |
| Net Income | 59,556.00 |
| EBITDA | -523,619.00 |
| EBIT | -547,591.00 |
| Earnings Per Share (EPS) | 0.01 |
Balance Sheet
Rapid Therapeutic Science Laboratories, Inc. holds 2,160.00 in cash and equivalents against 3.79M in total debt, resulting in a net debt position of 3.45M. Total book value stands at -10.07M, with working capital of -4.11M providing operational flexibility.
| Cash & Cash Equivalents | 2,160.00 |
| Total Debt | 3.79M |
| Net Debt | 3.45M |
| Equity (Book Value) | -10.07M |
| Book Value Per Share | -1.26 |
| Working Capital | -4.11M |
Cash Flow
Rapid Therapeutic Science Laboratories, Inc. produced -566,601.00 in operating cash flow over the past twelve months. After subtracting 315,645.00 in capital expenditures, free cash flow totaled -250,956.00 - equivalent to -0.03 per share.
| Operating Cash Flow | -566,601.00 |
| Capital Expenditures | 315,645.00 |
| Free Cash Flow | -250,956.00 |
| FCF Per Share | -0.03 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -27.48 |
| FCF Yield | -172.00 |
Stock Splits
Rapid Therapeutic Science Laboratories, Inc.'s most recent stock split took place on March 31, 2022 with a 25:1 split ratio.
| Last Split Date | 3/31/2022 |
| Split Ratio | 25:1 |
Scores
Rapid Therapeutic Science Laboratories, Inc. posts an Altman Z-Score of -10.88, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -10.88 |